Reported deal values conflict. One outlet cites $40 billion, while Manila Times reporting that cites the EU puts it at $48.7 billion. Primary filings will settle the figure. Completion is expected in the second half of 2026, but only after the remedy is carried out and other customary closing conditions, including remaining foreign approvals, are met. The approval is conditional, so the divestiture is not optional for the deal to proceed as cleared.
For attorneys, the key items are the closing of the Dilek Grup sale and whether the remaining foreign approvals follow on the same timeline. The EU remedy follows similar feminine care divestments required in Australia and Brazil, which suggests regulators are treating this category as a consistent focus. EU competition chief Teresa Ribera said the commitment will preserve competition and affordable prices for women. The deal has already cleared U.S. Hart-Scott-Rodino review, which expired February 4, 2026, and shareholders of both companies approved it on January 29, 2026, so the EU decision is among the last major hurdles.